Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011;6(9):e25127.
doi: 10.1371/journal.pone.0025127. Epub 2011 Sep 28.

Enrollment characteristics and risk behaviors of injection drug users participating in the Bangkok Tenofovir Study, Thailand

Michael Martin  1 , Suphak Vanichseni, Pravan Suntharasamai, Udomsak Sangkum, Rutt Chuachoowong, Philip A Mock, Manoj Leethochawalit, Sithisat Chiamwongpaet, Somyot Kittimunkong, Frits van Griensven, Janet M McNicholl, Lynn Paxton, Kachit Choopanya; Bangkok Tenofovir Study Group
Collaborators, Affiliations
Clinical Trial

Enrollment characteristics and risk behaviors of injection drug users participating in the Bangkok Tenofovir Study, Thailand

Michael Martin et al. PLoS One. 2011.

Abstract

Background: The Bangkok Tenofovir Study was launched in 2005 to determine if pre-exposure prophylaxis with tenofovir will reduce the risk of HIV infection among injecting drug users (IDUs). We describe recruitment, screening, enrollment, and baseline characteristics of study participants and contrast risk behavior of Tenofovir Study participants with participants in the 1999-2003 AIDSVAX B/E Vaccine Trial.

Methods: The Bangkok Tenofovir Study is an ongoing, phase-3, randomized, double-blind, placebo-controlled, HIV pre-exposure prophylaxis trial of daily oral tenofovir. The Tenofovir Study and the Vaccine Trial were conducted among IDUs at 17 drug-treatment clinics in Bangkok. Tenofovir Study sample size was based on HIV incidence in the Vaccine Trial. Standardized questionnaires were used to collect demographic, risk behavior, and incarceration data. The Tenofovir Study is registered with ClinicalTrials.gov, number--NCT00119106.

Results: From June 2005 through July 2010, 4094 IDUs were screened and 2413 enrolled in the Bangkok Tenofovir Study. The median age of enrolled participants was 31 years (range, 20-59), 80% were male, and 63% reported they injected drugs during the 3 months before enrollment. Among those who injected, 53% injected methamphetamine, 37% midazolam, and 35% heroin. Tenofovir Study participants were less likely to inject drugs, inject daily, or share needles (all, p<0.001) than Vaccine Trial participants.

Discussion: The Bangkok Tenofovir Study has been successfully launched and is fully enrolled. Study participants are significantly less likely to report injecting drugs and sharing needles than participants in the 1999-2003 AIDSVAX B/E Vaccine Trial suggesting HIV incidence will be lower than expected. In response, the Bangkok Tenofovir Study enrollment was increased from 1600 to 2400 and the study design was changed from a defined 1-year follow-up period to an endpoint-driven design. Trial results demonstrating whether or not daily oral tenofovir reduces the risk of HIV infection among IDUs are expected in 2012.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Number of injection drug users screened and enrolled in the Bangkok Tenofovir Study in Bangkok, Thailand, 2005–2010.
See this image and copyright information in PMC

References

    1. Weniger BG, Limpakarnjanarat K, Ungchusak K, Thanprasertsuk S, Choopanya K, et al. The epidemiology of HIV infection and AIDS in Thailand. AIDS. 1991;5(Suppl. 2):S71–S85. - PubMed
    1. National AIDS Prevention and Alleviation Committee. UNGASS Country Progress Report, Thailand. Thailand Ministry of Public Health, Department of Disease Control. Available: http://data.unaids.org/pub/report/2008/thailand_2008_country_progress_re... Accessed 2011 May 26.
    1. WHO. Epidemiological Fact Sheet on HIV and AIDS, Thailand, 2008 update. Available: http://apps.who.int/globalatlas/predefinedReports/EFS2008/full/EFS2008_T... Accessed 2011 May 26.
    1. De Clercq E, Sakuma T, Baba M, Pauwels R, Balzarini J, et al. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res. 1987;8:261–272. - PubMed
    1. De Clercq E. Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections. Clin Microbiol Rev. 2003;16:569–596. - PMC - PubMed

Publication types

Associated data